Morphine-6-glucuronide disposition in renal impairment

Area of Science:

• Pharmacology
• Nephrology
• Anesthesiology

Background:

• Morphine-6-glucuronide (M6G) is a potent opioid analgesic.
• Its pharmacokinetics can be significantly altered in patients with renal dysfunction.
• Understanding M6G disposition is crucial for safe pain management in renally impaired patients.

Purpose of the Study:

• To investigate the pharmacokinetics of intravenous M6G in patients with chronic renal failure (CRF) compared to kidney transplant recipients.
• To assess the impact of peritoneal dialysis on M6G elimination in CRF patients.

Main Methods:

• A single intravenous dose of M6G (30 µg/kg) was administered to 12 dialysis-dependent CRF patients, 6 non-dialyzed CRF patients, and 6 kidney transplant recipients.
• Serum M6G concentrations were measured up to 12 hours post-administration using high-performance liquid chromatography.
• Pharmacokinetic parameters including elimination half-life and clearance were calculated for each group.

Main Results:

• M6G elimination half-life was significantly shorter in transplanted patients (2.14 h) compared to non-dialyzed CRF patients (27.10 h) and dialyzed CRF patients (17.33 h).
• M6G clearance was significantly greater in transplanted patients (96.0 ml/min) versus non-dialyzed (10.57 ml/min) and dialyzed CRF patients (14.3 ml/min).
• Peritoneal dialysis initiated 6 hours post-M6G administration showed a limited effect on M6G disposition compared to non-dialyzed CRF patients.

Conclusions:

• Kidney transplant recipients exhibit significantly more rapid M6G clearance than patients with chronic renal failure.
• M6G is eliminated slowly in patients with renal impairment, necessitating careful dosing.
• Peritoneal dialysis offers minimal benefit in accelerating M6G elimination in the studied timeframe.